Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status

W. R. Bezwoda, R. D. Dansey, C. S. Hesdorffer, S. Browde

Research output: Contribution to journalArticle

Abstract

In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%). Response was not determined either by the nature or the extent of previous treatment, including endocrine therapy and/or chemotherapy, nor by oestrogen-receptor status. The vast majority of patients who responded were postmenopausal but a complete response was seen in a premenopausal patient with skin metastases. Aminoglutethimide is useful in the second-line treatment of postmenopausal subjects with advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)107-109
Number of pages3
JournalSouth African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
Volume72
Issue number2
StatePublished - 1987
Externally publishedYes

Fingerprint

Aminoglutethimide
Estrogen Receptors
Breast Neoplasms
Hydrocortisone
Therapeutics
Neoplasm Metastasis
Drug Therapy
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status. / Bezwoda, W. R.; Dansey, R. D.; Hesdorffer, C. S.; Browde, S.

In: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, Vol. 72, No. 2, 1987, p. 107-109.

Research output: Contribution to journalArticle

@article{e78934e1093a4c73b8058860a259d03d,
title = "Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status",
abstract = "In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36{\%}). Response was not determined either by the nature or the extent of previous treatment, including endocrine therapy and/or chemotherapy, nor by oestrogen-receptor status. The vast majority of patients who responded were postmenopausal but a complete response was seen in a premenopausal patient with skin metastases. Aminoglutethimide is useful in the second-line treatment of postmenopausal subjects with advanced breast cancer.",
author = "Bezwoda, {W. R.} and Dansey, {R. D.} and Hesdorffer, {C. S.} and S. Browde",
year = "1987",
language = "English (US)",
volume = "72",
pages = "107--109",
journal = "South African Medical Journal",
issn = "0256-9574",
publisher = "South African Medical Association",
number = "2",

}

TY - JOUR

T1 - Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status

AU - Bezwoda, W. R.

AU - Dansey, R. D.

AU - Hesdorffer, C. S.

AU - Browde, S.

PY - 1987

Y1 - 1987

N2 - In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%). Response was not determined either by the nature or the extent of previous treatment, including endocrine therapy and/or chemotherapy, nor by oestrogen-receptor status. The vast majority of patients who responded were postmenopausal but a complete response was seen in a premenopausal patient with skin metastases. Aminoglutethimide is useful in the second-line treatment of postmenopausal subjects with advanced breast cancer.

AB - In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%). Response was not determined either by the nature or the extent of previous treatment, including endocrine therapy and/or chemotherapy, nor by oestrogen-receptor status. The vast majority of patients who responded were postmenopausal but a complete response was seen in a premenopausal patient with skin metastases. Aminoglutethimide is useful in the second-line treatment of postmenopausal subjects with advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023205730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023205730&partnerID=8YFLogxK

M3 - Article

C2 - 3616780

AN - SCOPUS:0023205730

VL - 72

SP - 107

EP - 109

JO - South African Medical Journal

JF - South African Medical Journal

SN - 0256-9574

IS - 2

ER -